Cargando…

Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

Detalles Bibliográficos
Autores principales:	Khan, I., Kaempf, A., Raghuwanshi, S., Chesnokov, M., Zhang, X., Wang, Z., Domling, A., Tyner, J. W., Camacho, C., Gartel, A. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444844/ https://www.ncbi.nlm.nih.gov/pubmed/37607920 http://dx.doi.org/10.1038/s41408-023-00898-4

Ejemplares similares

Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells
por: Chesnokov, Mikhail S., et al.
Publicado: (2021)

Mutual Regulation of FOXM1, NPM and ARF Proteins
por: Pandit, Bulbul, et al.
Publicado: (2015)

The antagonistic duality of NPM1 mutations in AML
por: Khan, Irum, et al.
Publicado: (2022)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
por: Chesnokov, Mikhail S, et al.
Publicado: (2021)

Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3A(mut)NPM1(mut) AMLs
por: Donato, Elisa, et al.
Publicado: (2022)

Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1(mut)) for the Treatment of NPM1(mut)-Acute Myeloid Leukemia
por: De Cicco, Marica, et al.
Publicado: (2023)

The oncogenic transcription factor FOXM1 and anticancer therapy
por: Gartel, Andrei L.
Publicado: (2012)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

NPM 1 Mutations in AML—The Landscape in 2023
por: Sharma, Naman, et al.
Publicado: (2023)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors
por: Gartel, Andrei L.
Publicado: (2014)

Thiazole Antibiotics Siomycin a and Thiostrepton Inhibit the Transcriptional Activity of FOXM1
por: Gartel, Andrei L.
Publicado: (2013)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

FoxM1 Is a General Target for Proteasome Inhibitors
por: Bhat, Uppoor G., et al.
Publicado: (2009)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
por: Mill, Christopher P., et al.
Publicado: (2023)

The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA
por: Wang, Ming, et al.
Publicado: (2011)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice
por: Muranyi, Andrew, et al.
Publicado: (2022)

The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein
por: Pianigiani, Giulia, et al.
Publicado: (2022)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

Honokiol is a FOXM1 antagonist
por: Halasi, Marianna, et al.
Publicado: (2018)

Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-Damage
por: Halasi, Marianna, et al.
Publicado: (2012)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells
por: Bhat, Uppoor G., et al.
Publicado: (2009)

Spontaneous remission in three cases of AML M5 with NPM1 mutation
por: Camus, Vincent, et al.
Publicado: (2015)

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
por: Mer, Arvind Singh, et al.
Publicado: (2021)

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
por: Falini, Brunangelo, et al.
Publicado: (2021)

Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML
por: Lopez, Amanda, et al.
Publicado: (2021)

NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML
por: Tregnago, Claudia, et al.
Publicado: (2021)

Current status and future perspectives in targeted therapy of NPM1-mutated AML
por: Ranieri, Roberta, et al.
Publicado: (2022)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

AKT regulates NPM dependent ARF localization and p53(mut) stability in tumors
por: Hamilton, Garth, et al.
Publicado: (2014)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2023)

P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

Targeting the CtBP1-FOXM1 transcriptional complex with small molecules to overcome MDR1-mediated chemoresistance in osteosarcoma cancer stem cells
por: Chen, Xun, et al.
Publicado: (2021)

Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells
por: Huang, Min, et al.
Publicado: (2016)

NPM1-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition
por: Hemsing, Anette Lodvir, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8tfijjf6rcoen4gjk7pn5iit9a